Decernotinib (VX-509)
CAS: 944842-54-0
Ref. 3D-UMB84254
| 25mg | A consultar | ||
| 50mg | A consultar | ||
| 100mg | A consultar |
Información del producto
- (2R)-2-Methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)butanamide
- (2R)-2-Methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide
- Adelatinib
- Butanamide, 2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)-, (2R)-
- V 509
- Vrt 831509
- Vx-509
Decernotinib is a small molecule inhibitor that binds to the ATP site of the polymerase chain reaction (PCR) enzyme. Decernotinib has shown efficacy in animal models of autoimmune diseases, such as alopecia areata and rheumatoid arthritis. It has also been shown to inhibit the response of primary cells isolated from patients with systemic lupus erythematosus and myasthenia gravis. The drug is expected to be used as an antirheumatic drug for the treatment of inflammatory diseases. Decernotinib has not yet been tested in humans, but it is predicted that this drug will have few side effects and no significant interactions with other drugs.
Propiedades químicas
Consulta técnica sobre: 3D-UMB84254 Decernotinib (VX-509)
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
